Lucero, Claudia M.Andrade, David C.Toledo, CamiloDíaz, Hugo S.Pereyra, Katherin V.Diaz-Jara, EstebanSchwarz, Karla G.Marcus, Noah J.Retamal, MauricioQuintanilla, Rodrigo A.Del Rio, Rodrigo2021-08-102021-08-102020Scientific Reports, 2020, vol.10:6878https://doi.org/10.1038/s41598-020-63336-6http://hdl.handle.net/11447/4280Alterations in connexins and specifcally in 43 isoform (Cx43) in the heart have been associated with a high incidence of arrhythmogenesis and sudden death in several cardiac diseases. We propose to determine salutary efect of Cx43 mimetic peptide Gap27 in the progression of heart failure. Highoutput heart failure was induced by volume overload using the arterio-venous fstula model (AV-Shunt) in adult male rats. Four weeks after AV-Shunt surgery, the Cx43 mimetic peptide Gap27 or scrambled peptide, were administered via osmotic minipumps (AV-ShuntGap27 or AV-ShuntScr) for 4 weeks. Cardiac volumes, arrhythmias, function and remodeling were determined at 8 weeks after AV-Shunt surgeries. At 8th week, AV-ShuntGap27 showed a marked decrease in the progression of cardiac deterioration and showed a signifcant improvement in cardiac functions measured by intraventricular pressure-volume loops. Furthermore, AV-ShuntGap27 showed less cardiac arrhythmogenesis and cardiac hypertrophy index compared to AV-ShuntScr. Gap27 treatment results in no change Cx43 expression in the heart of AV-Shunt rats. Our results strongly suggest that Cx43 play a pivotal role in the progression of cardiac dysfunction and arrhythmogenesis in high-output heart failure; furthermore, support the use of Cx43 mimetic peptide Gap27 as an efective therapeutic tool to reduce the progression of cardiac dysfunction in high-output heart failure.enCx43Gap27Cardiac diseasesArticle